The Cigna Group(CI)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
CI | 81.02 B | 11.99x | 6.70% | 2.27% | $25.58 | 16.76% | 0.74x | 2.05% | $311.34 | $239.51 |
CVS | 121.18 B | 23.57x | 7.10% | 1.18% | $4.02 | 6.21% | 0.95x | 2.87% | $110.00 | $68.48 |
LH | 26.21 B | 26.42x | 5.80% | 6.99% | $12.23 | 11.73% | 0.79x | 0.89% | $341.07 | $242.07 |
DGX | 26.17 B | 24.86x | 10.20% | 9.19% | $9.54 | 14.60% | 0.81x | 1.39% | $247.92 | $168.35 |
Peer Valuation & Performance Analysis
Peer group analysis for The Cigna Group (CI) compared to its primary competitors (including CVS, LH, DGX) reveals distinct metrics. CI trades at a valuation discount relative to its competitors, with a P/E ratio of 12.0x versus the peer average of 24.9x (representing a 52% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, CI's revenue growth of 6.7% is consistent with the peer average of 7.7%. Additionally, its net margin of 2.3% is below the peer average of 5.8%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• CI ranks #1 in P/E ratio, #3 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $302.00 | $307.00 | $300.86 | $306.60 | 1,440,321 | +2.71% |
| 2026-10-19 | $299.00 | $302.15 | $296.32 | $298.50 | 1,228,600 | -1.26% |
| 2026-10-16 | $301.00 | $303.08 | $298.23 | $302.30 | 1,545,500 | +1.17% |
| 2026-10-15 | $293.50 | $300.11 | $292.47 | $298.81 | 2,072,100 | +3.19% |
| 2026-10-14 | $283.85 | $290.08 | $283.56 | $289.58 | 1,396,400 | +2.50% |
| 2026-10-13 | $287.20 | $289.35 | $277.43 | $282.53 | 1,540,500 | -0.29% |
| 2026-10-12 | $283.36 | $285.55 | $281.36 | $283.34 | 970,600 | +0.32% |
| 2026-10-09 | $281.16 | $287.89 | $280.46 | $282.43 | 885,400 | +0.50% |
| 2026-10-08 | $278.98 | $282.42 | $275.32 | $281.03 | 1,552,800 | +0.90% |
| 2026-10-07 | $274.88 | $283.13 | $274.76 | $278.51 | 1,632,900 | +1.51% |
| 2026-10-06 | $271.72 | $275.82 | $270.00 | $274.37 | 1,093,400 | +1.14% |
| 2026-10-05 | $270.00 | $273.11 | $266.46 | $271.29 | 1,536,000 | +0.28% |
| 2026-10-02 | $270.03 | $271.40 | $266.00 | $270.53 | 1,914,100 | +0.96% |
| 2026-10-01 | $275.97 | $275.97 | $262.85 | $267.96 | 1,981,000 | -1.42% |
| 2026-09-30 | $274.03 | $278.88 | $263.36 | $271.83 | 3,080,100 | -1.25% |
Explore More Analysis for CI
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.